HOME >> BIOLOGY >> NEWS
UCSD discovery opens new avenues for design of anti-tumor medications

ors were starved of oxygen and nutrients, resulting in tumors were smaller in size than in normal mice and had dead tissue at their centers.

To date, most efforts to develop angiogenesis inhibitors--drugs to prevent growth of blood vessels-- have focused on inhibiting the signals sent out by the tumor in response to low oxygen. These latest findings suggest that targeting the endothelial cells' response to low oxygen is a viable alternative strategy to the development of angiogenesis inhibitors. Furthermore, the researchers point out that it may be easier to design effective treatments that target the endothelial cells rather than the tumor cells.

"Cancer cells mutate frequently," says Nan Tang, a graduate student working with Johnson and the first author on the paper. "This means that it is common for these cells to develop resistance to drugs. On the other hand, the endothelial cells are normal cells and would be much less likely to develop drug resistance."

"The endothelial cells are also in direct contact with the blood, simplifying the delivery of drugs," adds Tang.

Because HIF-1alpha is usually turned off in endothelial cells, and the mice lacking the gene in blood vessels were healthy and had normal lifespans, the researchers think that inhibiting the blood vessels' response to low oxygen should be relatively safe. One caveat is that interfering with blood vessels' response to low oxygen may also inhibit wound healing, as was observed in the mice lacking HIF-1alpha. According to the researchers, further work will be needed before their discovery can be applied to actually design new anti-tumor drugs.

"Since the response of the blood vessels to low oxygen likely involves multiple genes and chemical signals, we still need to tease apart the steps involved in the response," says Johnson. "It will also be important to understand how the signals sent out by the tumor, to stimulate t
'"/>

Contact: Kim McDonald
kmcdonald@ucsd.edu
858-534-7572
University of California - San Diego
15-Nov-2004


Page: 1 2 3

Related biology news :

1. Enzyme discovery sheds light on vitamin D
2. New proteomics research promises to revolutionize biomedical discovery
3. MU researchers make discovery in molecular mechanics of phototropism
4. International team to honor 30th anniversary of deep-sea vent discovery in Galpagos
5. Screening approach leads to discovery of gene linked to breast cancer
6. Lucky 13 as new gene discovery offers further hope for childhood blindness
7. Plants that produce more vitamin C may result from UCLA-Dartmouth discovery
8. Biting discovery: MU entomologist finds host of new aquatic insect species in Thailand
9. J&JPRD discovery may lead to new treatments for chronic sensitivity, pain caused by cold
10. Protein enables discovery of quantum effect in photosynthesis
11. Unicellular microRNA discovery

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: UCSD discovery opens new avenues for design anti tumor medications

(Date:8/26/2015)... The report "Multi-Factor Authentication (MFA) Market ... (Travel & Immigration, Government, Banking, Defense, Commercial Security, Consumer ... published by MarketsandMarkets, Multi-Factor Authentication Market is expected to ... CAGR of 17.7% between 2015 and 2020. ... spread through 169 P ages and ...
(Date:8/24/2015)... CAPE TOWN, South Africa , August 24, 2015 /PRNewswire/ ... awarded Germany ,s largest biometrics manufacturer DERMALOG ... with the "2015 African Biometrics Company of the ... installation in Nigeria .   ... ) and http://www.presseportal.de/nr/8896 - On Thursday ...
(Date:8/20/2015)... Aug. 20, 2015 The wearable technology ... are active and healthy. However, wearable technology has ... environment to help improve diagnostic capabilities and therapeutic ... the Wearable Technologies Conference 2015 , where ... for wearables in healthcare.    "Over ...
Breaking Biology News(10 mins):Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 2Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 3Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 4Multi-Factor Authentication Market Worth 9.60 Billion USD by 2020 5Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3
(Date:8/26/2015)... - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ICO) ... quarter ended June 30, 2015. Amounts, unless specified ... under International Financial Reporting Standards ("IFRS"). ... Oral Amp B program, rapidly advancing towards the ... Rae , President & CEO of iCo Therapeutics. "We ...
(Date:8/26/2015)... ... August 26, 2015 , ... Lee Biosolutions, a global ... and manufacture of highly valued cardiac markers used in early detection of heart ... protein chemistry has led to the development and commercialization of important cardiac biomarkers ...
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic company ... has received a $1.5M Phase II SBIR grant ... further develop its therapeutic agent to reduce arteriovenous ... in end stage renal disease (ESRD) patients undergoing ... Institute of Diabetes and Digestive and Kidney Diseases ...
(Date:8/26/2015)... and BEIJING , August 26, 2015 ... Scene with Impressive Acheivements  DiaCardio wins 1 st ... The competition, led in Israel ... featured 21 startups from countries including the US, China ... and Latin America .  Impressive ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 2Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 3Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 4Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 5Israeli Startup Takes First Place at Shengjing Global Innovation Awards 2015 6
Cached News: